Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

CervoMed (CRVO) EBT (2022 - 2025)

Historic EBT for CervoMed (CRVO) over the last 10 years, with Q3 2025 value amounting to -$7.7 million.

  • CervoMed's EBT fell 6263.68% to -$7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$25.6 million, marking a year-over-year decrease of 11415.39%. This contributed to the annual value of -$16.3 million for FY2024, which is 11452.27% down from last year.
  • As of Q3 2025, CervoMed's EBT stood at -$7.7 million, which was down 6263.68% from -$6.2 million recorded in Q2 2025.
  • CervoMed's EBT's 5-year high stood at -$1.2 million during Q2 2023, with a 5-year trough of -$7.7 million in Q3 2025.
  • Its 4-year average for EBT is -$3.8 million, with a median of -$2.8 million in 2022.
  • In the last 5 years, CervoMed's EBT skyrocketed by 4205.55% in 2023 and then tumbled by 18404.8% in 2024.
  • Quarter analysis of 4 years shows CervoMed's EBT stood at -$4.1 million in 2022, then surged by 42.06% to -$2.4 million in 2023, then tumbled by 184.05% to -$6.7 million in 2024, then decreased by 15.16% to -$7.7 million in 2025.
  • Its EBT stands at -$7.7 million for Q3 2025, versus -$6.2 million for Q2 2025 and -$4.9 million for Q1 2025.